MannKind’s inhalable insulin device Afrezza.

MannKind’s inhalable insulin device Afrezza.

Westlake Village-based MannKind Corp.’s shares closed up more than 11 percent Monday after the announcement of a Medicare policy change that lifts a restriction on diabetic patients having to choose between two tools to manage the condition. ...

Join our Membership to get the full story.


Are you a current Member? Sign In